| Guidelines for the use and interpretation of assays for monitoring autophagy (4th edition)1 DJ Klionsky, AK Abdel-Aziz, S Abdelfatah, M Abdellatif, A Abdoli, S Abel, ... autophagy 17 (1), 1-382, 2021 | 13164* | 2021 |
| Constitutive activation of Stat3 signaling confers resistance to apoptosis in human U266 myeloma cells R Catlett-Falcone, TH Landowski, MM Oshiro, J Turkson, A Levitzki, ... Immunity 10 (1), 105-115, 1999 | 2123 | 1999 |
| Bone marrow stromal-derived soluble factors and direct cell contact contribute to de novo drug resistance of myeloma cells by distinct mechanisms Y Nefedova, TH Landowski, WS Dalton Leukemia 17 (6), 1175-1182, 2003 | 329 | 2003 |
| Mutations in the Fas antigen in patients with multiple myeloma TH Landowski, N Qu, I Buyuksal, JS Painter, WS Dalton Blood, The Journal of the American Society of Hematology 90 (11), 4266-4270, 1997 | 323 | 1997 |
| Role of the tumor microenvironment in mediating de novo resistance to drugs and physiological mediators of cell death LA Hazlehurst, TH Landowski, WS Dalton Oncogene 22 (47), 7396-7402, 2003 | 267 | 2003 |
| Mitochondrial-mediated disregulation of Ca2+ is a critical determinant of Velcade (PS-341/bortezomib) cytotoxicity in myeloma cell lines TH Landowski, CJ Megli, KD Nullmeyer, RM Lynch, RT Dorr Cancer research 65 (9), 3828-3836, 2005 | 263 | 2005 |
| Cell adhesion-mediated drug resistance (CAM-DR) is associated with activation of NF-κB (RelB/p50) in myeloma cells TH Landowski, NE Olashaw, D Agrawal, WS Dalton Oncogene 22 (16), 2417-2421, 2003 | 248 | 2003 |
| Dysregulation of CD95/CD95 Ligand-Apoptotic Pathway in CD3+ Large Granular Lymphocyte Leukemia T Lamy, JH Liu, TH Landowski, WS Dalton, TP Loughran Jr Blood, The Journal of the American Society of Hematology 92 (12), 4771-4777, 1998 | 196 | 1998 |
| Selection for drug resistance results in resistance to Fas-mediated apoptosis TH Landowski, MC Gleason-Guzman, WS Dalton Blood, The Journal of the American Society of Hematology 89 (6), 1854-1861, 1997 | 192 | 1997 |
| Inhibition of Bcr–Abl kinase activity by PD180970 blocks constitutive activation of Stat5 and growth of CML cells M Huang, JF Dorsey, PK Epling-Burnette, R Nimmanapalli, TH Landowski, ... Oncogene 21 (57), 8804-8816, 2002 | 187 | 2002 |
| Studies of the structure of the metastasis-associated 67 kDa laminin binding protein: fatty acid acylation and evidence supporting dimerization of the 32 kDa gene product to … TH Landowski, EA Dratz, JR Starkey Biochemistry 34 (35), 11276-11287, 1995 | 153 | 1995 |
| Adhesion-mediated intracellular redistribution of c-Fas-associated death domain-like IL-1-converting enzyme-like inhibitory protein-long confers resistance to CD95-induced … KH Shain, TH Landowski, WS Dalton The Journal of Immunology 168 (5), 2544-2553, 2002 | 152 | 2002 |
| The tumor microenvironment as a determinant of cancer cell survival: a possible mechanism for de novo drug resistance KH Shain, TH Landowski, WS Dalton Current opinion in oncology 12 (6), 557-563, 2000 | 127 | 2000 |
| Combined treatment with the checkpoint abrogator UCN-01 and MEK1/2 inhibitors potently induces apoptosis in drug-sensitive and-resistant myeloma cells through an IL-6 … Y Dai, TH Landowski, ST Rosen, P Dent, S Grant Blood, The Journal of the American Society of Hematology 100 (9), 3333-3343, 2002 | 115 | 2002 |
| The farnesyl transferase inhibitor, FTI-277, inhibits growth and induces apoptosis in drug-resistant myeloma tumor cells SCE Bolick, TH Landowski, D Boulware, MM Oshiro, J Ohkanda, ... Leukemia 17 (2), 451-457, 2003 | 94 | 2003 |
| Multiple myeloma: new insights and therapeutic approaches KC Anderson, RA Kyle, WS Dalton, T Landowski, K Shain, R Jove, ... ASH Education Program Book 2000 (1), 147-165, 2000 | 94 | 2000 |
| Myeloma cells selected for resistance to CD95-mediated apoptosis are not cross-resistant to cytotoxic drugs: evidence for independent mechanisms of caspase activation TH Landowski, KH Shain, MM Oshiro, I Buyuksal, JS Painter, WS Dalton Blood, The Journal of the American Society of Hematology 94 (1), 265-274, 1999 | 90 | 1999 |
| Inhibition of JAK kinase activity enhances Fas-mediated apoptosis but reduces cytotoxic activity of topoisomerase II inhibitors in U266 myeloma cells MM Oshiro, TH Landowski, R Catlett-Falcone, LA Hazlehurst, M Huang, ... Clinical cancer research 7 (12), 4262-4271, 2001 | 76 | 2001 |
| Gemcitabine resistant pancreatic cancer cell lines acquire an invasive phenotype with collateral hypersensitivity to histone deacetylase inhibitors BK Samulitis, KW Pond, E Pond, AE Cress, H Patel, L Wisner, C Patel, ... Cancer biology & therapy 16 (1), 43-51, 2015 | 67 | 2015 |
| Control pathways of the 67 kDa laminin binding protein: surface expression and activity of a new ligand binding domain TH Landowski, S Uthayakumar, JR Starkey Clinical & Experimental Metastasis 13, 357-372, 1995 | 64 | 1995 |
